BACKGROUND: First-line treatment for chronic urticaria is H1 non-sedating antihistamines. When these fail, guidelines recommend combination with H2 antihistamines. AIM: We conducted a randomized, double-blind, placebo-controlled trial. METHODS:Thirty-two patients with chronic urticaria were included. Group A (16 subjects) treated with cetirizine plus ranitidine and Group B (16 subjects) with cetirizine plus placebo, both for 30 days. Efficacy measures were Urticaria Activity Score (UAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and time of symptom remission, safety measures were clinical and laboratory effects. RESULTS:Complete remission was obtained in ten patients (62.5%) from Group A and seven patients (44%) from Group B (p = 0.28). The UAS in Group A was 1.53 ± 2.09 versus Group B 2.06 ± 1.34 (p = 0.20). The CU-Q2oL in Group A was 12.93 ± 19.20 versus Group B 12.68 ± 10.30 (p = 0.20). At the end of treatment, 13 patients (81%) from Group A and 14 patients (87.5%) from Group B had some type of adverse effect (p = 1.0). CONCLUSIONS: Combination of cetirizine with ranitidine was not more effective than cetirizine alone in chronic urticaria. Both treatments resulted equally safe; however, our main limitation is the small sample size.
RCT Entities:
BACKGROUND: First-line treatment for chronic urticaria is H1 non-sedating antihistamines. When these fail, guidelines recommend combination with H2 antihistamines. AIM: We conducted a randomized, double-blind, placebo-controlled trial. METHODS: Thirty-two patients with chronic urticaria were included. Group A (16 subjects) treated with cetirizine plus ranitidine and Group B (16 subjects) with cetirizine plus placebo, both for 30 days. Efficacy measures were Urticaria Activity Score (UAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and time of symptom remission, safety measures were clinical and laboratory effects. RESULTS: Complete remission was obtained in ten patients (62.5%) from Group A and seven patients (44%) from Group B (p = 0.28). The UAS in Group A was 1.53 ± 2.09 versus Group B 2.06 ± 1.34 (p = 0.20). The CU-Q2oL in Group A was 12.93 ± 19.20 versus Group B 12.68 ± 10.30 (p = 0.20). At the end of treatment, 13 patients (81%) from Group A and 14 patients (87.5%) from Group B had some type of adverse effect (p = 1.0). CONCLUSIONS: Combination of cetirizine with ranitidine was not more effective than cetirizine alone in chronic urticaria. Both treatments resulted equally safe; however, our main limitation is the small sample size.
Authors: Woo Jung Song; Mira Choi; Dong Hun Lee; Jae Woo Kwon; Gun Woo Kim; Myung Hwa Kim; Mi Ae Kim; Min Hye Kim; Byung Keun Kim; Sujeong Kim; Joung Soo Kim; Jung Eun Kim; Ju Young Kim; Joo Hee Kim; Hyun Jung Kim; Hye One Kim; Hyo Bin Kim; Joo Young Roh; Kyung Hee Park; Kui Young Park; Han Ki Park; Hyunsun Park; Jung Min Bae; Ji Yeon Byun; Dae Jin Song; Young Min Ahn; Seung Eun Lee; Young Bok Lee; Joong Sun Lee; Ji Hyun Lee; Kyung Hwan Lim; Young Min Ye; Yoon Seok Chang; You Hoon Jeon; Jiehyun Jeon; Mihn Sook Jue; Sun Hee Choi; Jeong Hee Choi; Gyu Young Hur; Young Min Park; Dae Hyun Lim; Sang Woong Youn Journal: Allergy Asthma Immunol Res Date: 2020-07 Impact factor: 5.764
Authors: Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell Journal: World Allergy Organ J Date: 2021-06-01 Impact factor: 4.084